Your browser doesn't support javascript.
loading
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Veitch, Zachary W; Cescon, David W; Denny, Trisha; Yonemoto, Lisa-Maria; Fletcher, Graham; Brokx, Richard; Sampson, Peter; Li, Sze-Wan; Pugh, Trevor J; Bruce, Jeffrey; Bray, Mark R; Slamon, Dennis J; Mak, Tak W; Wainberg, Zev A; Bedard, Philippe L.
Afiliação
  • Veitch ZW; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Cescon DW; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Denny T; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Yonemoto LM; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Fletcher G; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
  • Brokx R; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Sampson P; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Li SW; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Pugh TJ; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bruce J; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bray MR; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Slamon DJ; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Mak TW; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
  • Wainberg ZA; Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bedard PL; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA. ZWainberg@mednet.ucla.edu.
Br J Cancer ; 121(4): 318-324, 2019 08.
Article em En | MEDLINE | ID: mdl-31303643
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Serina-Treonina Quinases / Indazóis / Indóis / Neoplasias / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Serina-Treonina Quinases / Indazóis / Indóis / Neoplasias / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article